Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research
Jotup,
The article, entitled "mDKN-01, a Novel Anti-DKK1 Monoclonal Antibody, Enhances Innate Immune Responses in the Tumor…
The article, entitled "mDKN-01, a Novel Anti-DKK1 Monoclonal Antibody, Enhances Innate Immune Responses in the Tumor…
- Results demonstrate that DKN-01 activity is both immune dependent and enhanced in combination with anti-PD-1 antibodies …
- Results demonstrate that DKN-01 activity is both immune dependent and enhanced in combination with anti-PD-1 antibodies …
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on…
- Results demonstrate that DKN-01 activity is both immune dependent and enhanced in combination with anti-PD-1 antibodies …
- Results demonstrate that DKN-01 activity is both immune dependent and enhanced in combination with anti-PD-1 antibodies …
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on…
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ --. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and…
CAMBRIDGE, Mass., Dec. 22, 2020 / / -- Leap Therapeutics, Inc. (NASDAQ:), a biotechnology company focused on developing…
Leap Therapeutics Announces Publication of DKN-01 Mechanism of Action Data in Molecular Cancer Research - Results demonstrate…
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ --. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and…
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on…
- Results demonstrate that DKN-01 activity is both immune dependent and enhanced in combination with anti-PD-1 antibodies …
- Results demonstrate that DKN-01 activity is both immune dependent and enhanced in combination with anti-PD-1 antibodies …
CAMBRIDGE, Mass., Dec. 22, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on…